Biofrontera Inc. Common Stock (BFRI)

About BFRI

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massac…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

84

Website

www.biofrontera-us.com

Fundamentals

1-day range

$1.26$1.4

Market cap

$15.24M

P/E (trailing)

—

P/E (forward)

4.06

EPS (trailing)

$-0.98

Dividend yield

—

Beta

0.80

Avg. volume

325.4K

Forecasts

2 analyst ratings

Biofrontera Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• BFRI

  Biofrontera Inc. Common Stock

  $1.59

  ▲ 6.38%
  Market cap $15.24MP/E —
  $0.555$1.4
• KALA

  KALA BIO Inc. Common Stock

  $0.6949

  ▼ 14.42%
  Market cap $15.14MP/E —
  $0.5867$1,030
• CYCN

  Cyclerion Therapeutics Inc. Common Stock

  $3.81

  ▼ 4.51%
  Market cap $15.11MP/E —
  $1.03$8.48
• KTTA

  Pasithea Therapeutics Corp. Common Stock

  $0.5975

  ▲ 7.66%
  Market cap $14.92MP/E —
  $0.281$2.06
• PTN

  Palatin Technologies Inc. Common Stock

  $10.48

  ▼ 0.10%
  Market cap $14.64MP/E 85.09
  $5.61$31
• AEON

  AEON Biopharma Inc. Class A Common Stock

  $0.3095

  ▲ 5.27%
  Market cap $14.41MP/E —
  $0.1772$1.45
• MDCX

  Medicus Pharma Ltd. Common Stock

  $0.258

  ▼ 3.73%
  Market cap $16.60MP/E —
  $0.2425$3.05

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Biofrontera Inc (BFRI) (Q2 2026) Earnings Call Highlights: Strong Ameluz Growth Drives Revenue ...
  Yahoo · 8/13/2026
• Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/13/2026
• Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates
  Yahoo · 8/13/2026
• Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
  Yahoo · 8/13/2026
• Biofrontera Q2 EPS $(0.05) Misses $(0.04) Estimate, Sales $12.003M Beat $10.500M Estimate
  Benzinga · 8/13/2026
• BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates
  Yahoo · 8/12/2026
• Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
  Yahoo · 8/5/2026

• Hermann Luebbert · March 5, 2026 · Option Exercise

  137.5K
• Eugene Frederick Leffler · March 5, 2026 · Option Exercise

  87.5K
• Weber Kevin Daniel · March 4, 2026 · Grant

  20.0K
• Hermann Luebbert · March 4, 2026 · Grant

  125.0K
• Eugene Frederick Leffler · March 4, 2026 · Grant

  62.5K
• Lanckriet Heikki · March 4, 2026 · Grant

  20.0K
• Hoffman Beth J. · March 4, 2026 · Grant

  20.0K
• Jones George Patrick · March 4, 2026 · Grant

  50.0K
• BORER JOHN J III · March 4, 2026 · Grant

  20.0K

Institutional Ownership

March 31, 2026

Total shares held

2.33M

Total value held

$1.89M

Institutional holders

11